Disease Modification -Sustainable influence on atopic dermatitis with systemic therapies

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, which is associated with a significant impairment of quality of life. In recent years, various biologics and Janus kinase inhibitors have been approved for the treatment of AD, which are directed in particular against this type 2 immune response. However, the extent to which long-term disease modification occurs during treatment has not yet been extensively investigated. As part of the Memorial Fellowship, this topic will be investigated over two years with the help of clinical and various "omics" data. The aim is to detect possible persistent inflammatory patterns and to characterise persistent anti-inflammatory mechanisms that can have a lasting influence on the course of the disease.